New Delhi: Miltenyi Biotec and the Translational Health Science and Technology Institute (THSTI) have partnered to launch India’s first hands-on training program in CAR-T cell and gene therapy manufacturing.
Signed under the aegis of BIRAC, the initiative marks a major step toward building skilled manpower in the country’s cell and gene therapy (CGT) ecosystem. The program will be hosted at THSTI’s GMP facility, using Miltenyi’s automated platforms like the CliniMACS Prodigy® and MACSQuant® Analyzer.
Trainees will receive joint certification in CAR-T cell manufacturing, quality control, and analytics through a curriculum combining theory with real-world lab experience.
“This is a strategic investment in India’s CGT infrastructure,” said Dr. Priya Kapoor-G Hingorani, MD – Miltenyi Biotec India. THSTI Executive Director Prof. Ganesan Karthikeyan added that the collaboration would accelerate the adoption of advanced therapies in India.
The initiative aims to build a pipeline of certified professionals, strengthen translational research, and improve patient access to cutting-edge treatments.
